- In October 2024, PacBio entered a Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS) to accelerate cancer research in Asia. The project will use PacBio's Onso short-read and Kinnex long-read sequencing technologies, focusing on profiling common cancers in the region, particularly through single-cell RNA sequencing
- In June 2024, Bio-Rad Laboratories, Inc. announced the launch of the ddSEQTM Single-Cell 3' RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research. The ddSEQ Single-Cell 3' RNA-Seq Kit delivers high-quality single-cell 3' RNA-Seq libraries in a fast, efficient, and affordable workflow, allowing researchers to easily conduct single-cell gene expression and regulation analyses
- In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced a collaboration aimed at expanding local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients. This initiative will target over 30 countries across Latin America, Africa, the Middle East, and Asia, where advanced genomic testing has been previously limited or inaccessible
- In July 2023, Institut Curie and Agilent introduced an advanced comprehensive genomic profiling kit designed to identify key genetic abnormalities driving cancer. The kit's functionality was demonstrated in the SHIVA02 clinical trial and is now being utilized in routine practice as part of the molecular RCP conducted by Institut Curie’s Department of Drug Development and Innovation
- In April 2020, Mission Bio, Inc. announced a partnership with Agilent Technologies to promote the adoption of Mission Bio's Tapestri Platform, the first and only multi-omic device capable of analyzing both DNA and protein at the single-cell level. This collaboration aims to provide the necessary tools to develop new treatments and potentially cures for cancer
